Eric B. Lev
Eric, who joined Ampersand in 2013, has 15 years of middle market healthcare investment experience. His board seats have included CutisPharma, Genoptix, LakePharma and Nexcelom. Most recently, he spent seven years as a member of the investment team at Water Street Healthcare Partners. Prior to Water Street, Eric worked at Beckman Coulter and One Equity Partners. Eric holds a BA in Economics from Northwestern University and a MBA from the University of Chicago.
Herbert H. Hooper
Herb is a managing partner at Ampersand Capitalsince 2002. Prior to Ampersand, Herb was a co-founder and chief scientific officer of Aclara Biosciences, a pioneering lab-on-a chip company that completed an IPO in 2000. Herb holds a PhD in Chemical Engineering from the University of California, Berkeley, and a BS in Chemical Engineering from NC State University. He has served as a board member for over a dozen public and private life sciences companies. Herb also serves on the Advisory Board for UC Berkeley’s College of Chemistry.
Laurence R. McCarthy
Larry, who joined as an Operating Partner in 2007, serves as a Board member of Bako and Genoptix. Previously, Larry was the Chairman and Chief Technology Officer of Focus Diagnostics, where he built Focus from a $2 million business to a leading esoteric lab with over $80 million in revenues before its acquisition by Quest Diagnostics in 2006. Prior to Focus, Larry held senior positions at Boehringer Mannheim and Becton Dickinson. He holds a PhD in Microbiology from the University of New Hampshire and served on the faculty of Johns Hopkins and at the University of North Carolina.
Benoit spent over 30 years growing healthcare businesses and solving fast growth-related issues as an entrepreneur, advisor and deal maker, or independent board member.
He has an unrivaled experience in pharmaceutical outsourcing. He created and led an advisory firm, a central lab, and a clinical project monitoring unit, the three business units of which became the leading clinical stage CRO in Continental Europe in the late 90s with over 400 people, mainly located in France, Italy, and Germany. He was a board member at Mapi Group, then a late-phase CRO with a few dozen of people, which today is the world leader in late-phase, patient-centered research with 800 people and revenues north of €100m.
Benoit has a dual scientific (PharmD Pharmacy 1984; PhD Pharmaceutical Sciences/Biotechnology 1986) and business (Advanced Management Program Harvard Business School 2002) education. His professional background enabled him to gain an in-depth knowledge of all aspects of a healthcare venture stage company and to favor understanding and collaboration between scientists and business persons.
In the investment banking field, he has been the head of Puilaetco (since acquired by KBC) research team between 1998 and 2002, instrumental in the emergence of a fund investing in innovative healthcare companies and of what became the reference M&A healthcare team in Europe (Bryan Garnier). He sourced and led the execution of over 40 M&A transactions and financing rounds for biotechnology and medical device companies, or CROs. He is an advisor to IMAP, a 400 M&A professional network with a presence in over 40 countries, ranked in the worldwide top 5 Thomson Financials league tables in the small and mid-markets for many years.